Takeaway

• A new review article in  JAMA Oncology  covers the landscape of current and investigational treatments for small cell lung cancer (SCLC), an aggressive disease that is often difficult to treat.
• Several recent approvals for metastatic SCLC are immunotherapies, as well as an agent that inhibits oncogenic transcription.

Why this...